WALTHAM, MASSACHUSETTS — Cytel Inc., a leading provider of innovative clinical trial designs, advanced analytics, and software solutions for developing new therapeutics, is pleased to announce the launch of the Cytel Design Institute (CDI).
Rooted in Cytel’s commitment to advancing the science of trial design and therapeutics development, the CDI creates a virtual network of leading minds in the various disciplines contributing to therapeutics development. As a living repository, the CDI captures and illustrates how impactful contributions from talented colleagues are moving new candidate medicines and medical devices forward toward patients in need.
According to Cytel CEO Joshua Schultz, “The CDI was built on two key convictions – the need for innovative new methods to get life-saving therapies to market, and the unmet need for more quantitative insight across the therapeutics development spectrum. While we have always built new methods for statistical testing, we also take particular pride in diffusing innovation throughout the industry, bringing innovations to the larger market with our software and expert consultants.”
Building on Cytel’s academic heritage and its founders’ significant scientific contributions, the CDI offers a holistic resource hub to explore critical topics in therapeutics development, including the future of clinical trial design, the evolving landscape in biotherapeutics, complex adaptive trial design, and new digital development platforms, like Solara®.
“Our industry is remarkably dynamic,” says Dr. Albert Kim, Cytel’s Chief Medical Officer. “In founding the CDI, we hope to help bridge the history of scientific advances in trial design to its evolving future. We’re excited to help provide a resource for everyone to learn about and celebrate innovative ways to generate meaningful data for new therapeutics.”
To learn more about the CDI, visit the newly launched website: https://www.cytel.com/cytel-design-institute.
About Cytel
Cytel is the largest provider of statistical software and advanced analytics for clinical trial design and execution. For over thirty-five years, Cytel’s scientific rigor and operational excellence have enabled biotech and pharmaceutical companies to navigate uncertainty, prove value and make confident, evidence-based decisions. Its experts deliver industry-leading software, data-driven analytics, real-world evidence and strategic consulting. Headquartered in Waltham, Massachusetts, Cytel has more than 2,000 employees across North America, Europe and Asia. For more information about Cytel, please visit us at www.cytel.com
